GILD · 10-Q · 2026Q3 · Full report

Operating Expense Trends

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 40 · Surprise 48 · No source text

Selling, general and administrative expenses increased 21% to $1.6 billion for the three months ended September 30, 2026, and 26% to $5.0 billion for the nine months. Selling and marketing costs rose primarily because of higher HIV promotional expenses. General and administrative costs increased due to integration expenses from the Arcellx, Ouro Medicines and Tubulis acquisitions, including $332 million of nine-month stock-based compensation, as well as donations of equity securities to the Gilead Foundation, legal expenses and employee-related costs.

Key facts

• Gilead reported net income of $2.4 billion and diluted EPS of $1.94 for Q3 2026, versus net income of $3.1 billion and diluted EPS of $2.43 in Q3 2025. source
• Gilead’s SG&A expenses increased 21% to $1.6 billion in Q3 2026, with selling and marketing costs primarily higher due to HIV promotions and general and administrative costs primarily higher due to acquisition integration, legal matters and employee costs. source
• Gilead’s SG&A expenses increased 26% to $5.0 billion for the first nine months of 2026; acquisition integration included $332 million of stock-based compensation expenses. source
• Gilead reported a $6.0 billion net loss and diluted loss per share of $4.87 for the nine months ended September 30, 2026, versus net income of $6.3 billion and diluted EPS of $5.04 in 2025. source
• Gilead’s Q3 2026 net income decline was primarily due to equity-security net losses versus gains in 2025, higher operating expenses and higher income tax expense, partly offset by higher revenues and lower acquired IPR&D expenses. source

Impact estimates